Summit Research Initiates Imperva At Buy


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Summit Research initiated coverage on Imperva Inc (NYSE: IMPV) with a Buy rating.The target price for Imperva is set to $75.Imperva shares have gained 171.59 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period.Imperva shares fell 0.15 percent to close at $67.00 on Thursday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: InitiationAnalyst RatingsSummit Research